« Previous
Next »
Titles
- ANDA submissions--amendments to abbreviated new drug applications under GDUFA1
- Acne vulgaris: establishing effectiveness of drugs intended for treatment1
- Adolescent and young adult substance use: federal grants for prevention, treatment, and recovery services and for research : report to Congressional committees1
- Allergic rhinitis: developing drug products for treatment1
- Anthrax: developing drugs for prophylaxis of inhalational anthrax1
- Appropriate use of voluntary consensus standards in premarket submissions for medical devices: guidance for industry and Food and Drug Administration staff1
- Assessing user fees under the Prescription Drug User Fee Amendments of 20171
- Assessing user fees under the biosimilar user fee amendments of 20171
- Assessment and synthesis of selected Medicaid eligibility, enrollment, and renewal processes and systems in six states1
- BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment1
- Bioanalytical method validation1
- CMS did not detect some inappropriate claims for durable medical equipment in nursing facilities1
- Chronic obstructive pulmonary disease: use of the St. George's Respiratory Questionnaire as a PRO assessment tool1
- Clarification of orphan designation of drugs and biologics for pediatric subpopulations of common diseases1
- Clinical trial imaging endpoint process standards1
- Complicated intra-abdominal infections: developing drugs for treatment1
- Complicated urinary tract infections: developing drugs for treatment1
- Compounded drug products that are essentially copies of a commercially available drug product under Section 503A of the Federal Food, Drug, and Cosmetic Act1
- Compounded drug products that are essentially copies of approved drug products under Section 503B of the Federal Food, Drug, and Cosmetic Act1
- Considerations for design, development, and analytical validation of next generation sequencing (NGS)--based in vitro diagnostics (IVDs) intended to aid in the diagnosis of suspected germline diseases: guidance for stakeholders and Food and Drug Administration staff1